Evidence map›Paper›PMID 26663441›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.

E Cantu, Y Suzuki, J M Diamond, J Ellis, J Tiwari, B Beduhn, J R Nellen, R Shah, N J Meyer, D J Lederer and 20 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The Lung Allograft Microbiome Associates with Pepsin, Inflammation, and Primary Graft Dysfunction.American journal of respiratory and critical care medicine · 2022
    Article
  5. Primary graft dysfunction: what we know.Journal of thoracic disease · 2021
    Review
  6. Review
  7. Toll-Interacting Protein in Pulmonary Diseases. Abiding by the Goldilocks Principle.American journal of respiratory cell and molecular biology · 2021
    Review
  8. Review
  9. Early Graft Dysfunction after Lung Transplantation.Current pulmonology reports · 2018
    Article
  10. Article
  11. Review
  12. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2017
    Review
  13. Peripheral Blood Gene Expression Changes Associated With Primary Graft Dysfunction After Lung Transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 1 country.

E CantuDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
Y SuzukiDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
J M DiamondPulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
J EllisDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
J TiwariDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
B BeduhnDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
J R NellenDivision of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA.
R ShahPulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
N J MeyerPulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
D J LedererDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, New York.
S M KawutPulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
S M PalmerDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, NC.
L D SnyderDivision of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, NC.
M G HartwigDivision of Cardiothoracic Surgery, Duke University, Durham, NC.
V N LamaDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Michigan, Ann Arbor, MI.
S BhoradeDivision of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL.
M CrespoDivision of Pulmonary, Allergy, and Critical Care, University of Pittsburgh, Pittsburgh, PA.
E DemissiePulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
K WilleDivision of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL.
J OrensDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Johns Hopkins University Hospital, Baltimore, MD.
P D ShahDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Johns Hopkins University Hospital, Baltimore, MD.
A WeinackerDivision of Pulmonary and Critical Care Medicine, Stanford University, Palo Alto, CA.
D WeillDivision of Pulmonary and Critical Care Medicine, Stanford University, Palo Alto, CA.
D WilkesDivision of Pulmonary, Allergy, Critical Care, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN.
D RoeDivision of Pulmonary, Allergy, Critical Care, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN.
L B WareDepartments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN.
F WangCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA.
R FengCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA.
J D ChristiePulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
Lung Transplant Outcomes Group
University of Pennsylvania · USDuke University · USIndiana University School of MedicineJohns Hopkins University · USStanford University · USColumbia University · USUniversity of Alabama at Birmingham · USUniversity of Chicago · USUniversity of Michigan–Ann Arbor · USUniversity of Pittsburgh · USVanderbilt University · US

Funding

Clinical Risk Factors for Primary Graft DysfunctionR01HL087115 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIE, JASON D · 2007 to 2017
$7.1M
Biomarker Profiles in the Diagnosis/Prognosis of ARDSU01HL081332 · NHLBI · VANDERBILT UNIVERSITY · PI WARE, LORRAINE B · 2005 to 2008
$6.0M
Genetics of primary graft dysfunctionR01HL081619 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIE, JASON D · 2007 to 2011
$3.9M
Obesity, Inflammation, and Lung Injury After Lung TransplantationR01HL114626 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHRISTIE, JASON D, LEDERER, DAVID J. · 2013 to 2016
$3.1M
The GOLD Study: Goal of Open Lung Ventilation in DonorsR01HL126176 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARE, LORRAINE B · 2015 to 2020
$2.8M
Core Clinical Centers for the CTSNUM1HL088953 · NHLBI · DUKE UNIVERSITY · PI SMITH, PETER K · 2013 to 2017
$2.5M
Role of anti-Col (V) immunity in primary graft dysfunctionR01HL096845 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIE, JASON D, WILKES, DAVID S · 2010 to 2013
$2.2M
Career Development for Genomic/Genetic Studies in Lung DiseasesK12HL090021 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 2007 to 2012
$2.0M
Mentored Patient-Oriented Research in Pulmonary Arterial HypertensionK24HL103844 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KAWUT, STEVEN M · 2011 to 2020
$1.6M
Mentored Patient Oriented Research in Lung TransplantationK24HL115354 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTIE, JASON D · 2012 to 2021
$1.2M
Lung Transplant donor: prediction, evaluation, and mechanismK23HL116656 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CANTU, EDWARD · 2013 to 2017
$872k
Long Pentraxin-3 genomics and outcomes after lung transplantationK23HL121406 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DIAMOND, JOSHUA M. · 2014 to 2017
$629k
NHLBI NIH HHS HL081332NHLBI NIH HHS HL081619NHLBI NIH HHS HL087115NHLBI NIH HHS HL090021NHLBI NIH HHS HL096845NHLBI NIH HHS HL114626NHLBI NIH HHS HL115354NHLBI NIH HHS HL116656NHLBI NIH HHS HL121406NHLBI NIH HHS HL126176NHLBI NIH HHS K12 HL090021NHLBI NIH HHS K23 HL116656NHLBI NIH HHS K23 HL121406NHLBI NIH HHS K24 HL103844NHLBI NIH HHS K24 HL115354NHLBI NIH HHS R01 HL081619NHLBI NIH HHS R01 HL087115NHLBI NIH HHS R01 HL096845NHLBI NIH HHS R01 HL114626NHLBI NIH HHS R01 HL126176NHLBI NIH HHS R03 HL135227NHLBI NIH HHS U01 HL081332NHLBI NIH HHS UM1 HL088953NIMHD NIH HHS L32 MD002363NIMHD NIH HHS L32 MD008850
6 · The paper itself

Abstract

The authors previously identified plasma plasminogen activator inhibitor-1 (PAI-1) level as a quantitative lung injury biomarker in primary graft dysfunction (PGD). They hypothesized that plasma levels of PAI-1 used as a quantitative trait could facilitate discovery of genetic loci important in PGD pathogenesis. A two-stage cohort study was performed. In stage 1, they tested associations of loci with PAI-1 plasma level using linear modeling. Genotyping was performed using the Illumina CVD Bead Chip v2. Loci meeting a p < 5 × 10(-4) cutoff were carried forward and tested in stage 2 for association with PGD. Two hundred ninety-seven enrollees were evaluated in stage 1. Six loci, associated with PAI-1, were carried forward to stage 2 and evaluated in 728 patients. rs3168046 (Toll interacting protein [TOLLIP]) was significantly associated with PGD (p = 0.006). The increased risk of PGD for carrying at least one copy of this variant was 11.7% (95% confidence interval 4.9-18.5%). The false-positive rate for individuals with this genotype who did not have PGD was 6.1%. Variants in the TOLLIP gene are associated with higher circulating PAI-1 plasma levels and validate for association with clinical PGD. A protein quantitative trait analysis for PGD risk prioritizes genetic variations in TOLLIP and supports a role for Toll-like receptors in PGD pathogenesis.

Indexed as

Quantitative Trait LociAdultBiomarkersFemaleFollow-Up StudiesGenetic VariationGenotypeHumansIntracellular Signaling Peptides and ProteinsLung TransplantationMaleMiddle AgedPhenotypePlasminogen Activator Inhibitor 1Primary Graft DysfunctionPrognosisBiomarkersIntracellular Signaling Peptides and ProteinsPlasminogen Activator Inhibitor 1SERPINE1 protein, humanTOLLIP protein, humandysfunctionimmuneinflammatoryischemia reperfusion injury (IRI)lung (allograft) functionlung diseaselung transplantationpulmonologysciencetranslational research

Identifiers

PMID26663441
PMCPMC4767612
OpenAlexW2191756586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.